[Life-prolonging effect of immunocell BAK (BRM activated killer) therapy--evidence based integrative medicine].
We devised an innovative type of immunocell therapy called biological response modifier (BRM)-activated killer (BAK) therapy, which utilizes most of non-MHC (major histocompatibility complex)-restricted lymphocytes, CD56-positive cells including gammadelta T cells and NK cells. CD56-positive cells are neuro-immune-endocrine (NIE) multifunctional, integrated cells. We enrolled 30 immunosuppressed patients whose immunosuppressive acidic protein (IAP) levels in serum were over 580 microg/ml, and 63 immunoreactive solid cancer outpatients whose IAP level in serum were under 580 microg/ml. Treated with BAK therapy, the mean survival time of immunosuppressed patients was 5.0 months. On the other hand, survival time of immunoreactive advanced postoperative patients (stage IV) and inoperable lung cancer patients (stage IIIb) was 27.1 months. BAK therapy has a life-prolonging effect without any adverse effects and maintains satisfactory quality of life (QOL) for advanced solid cancer patients. Based on this evidence, we propose what can be called Integrative medicine which is neither Western nor Chinese medicine.
Ebina
Takusaburo
T
Division of Immunology, Miyagi Cancer Center Research Institute.
D019002:CD56 Antigen / Q000032:analysis; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D007167:Immunotherapy / Q000379:methods*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*
D019002:CD56 Antigen; D007155:Immunologic Factors; D009363:Neoplasm Proteins; C030193:immunosuppressive acidic protein